Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Dupilumab shows promise in bullous pemphigoid

17 Jun 2020

Use of dupilumab appears to confer benefits in patients with bullous pemphigoid (BP), results of a recent study have shown. Treatment has resulted in disease clearance or satisfactory response in majority of the patients, including those in whom previous conventional therapy has failed.

The investigators carried out a case series of patients from five academic centres receiving dupilumab for BP. Patients were included if they had a clinical diagnosis of BP confirmed by lesional skin biopsy assessed by one of the following: hematoxylin and eosin staining, direct immunofluorescence, or enzyme-linked immunosorbent assay for BP180 or BP230, or both.

Thirteen patients (mean age, 76.8 years) met the eligibility criteria. Their average duration of BP prior to dupilumab initiation was 28.8 months (range, 1–60 months). Twelve of 13 patients (92.3 percent) achieved either disease clearance or satisfactory response.

Satisfactory response was defined as clinician documentation of disease improvement and patient desire to continue using the medication without documentation of disease clearance.

More than half of the patients (7/13, 53.8 percent) achieved total clearance of the BP. Of note, no adverse events were reported.

The study was limited by its small sample size, lack of a control group, lack of a standardized assessment tool, and lack of standardized safety monitoring.

“BP is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.